Abstract
A new generation of prostate cancer (PCa) biomarkers has emerged, including diagnostic serum and urine markers aimed at refining the identification high-grade tumors and tissue-based gene expression assays offering prognostic and predictive clinical information. Such tests seek to improve treatment-related decisions at multiple decision points, including initial diagnosis and following initial primary therapy. In this review, we aim to contextualize the body of evidence surrounding these emerging tests, with attention on studies addressing clinical utility.
from Cancer via ola Kala on Inoreader http://ift.tt/1PEayLp
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου